Table 1. Baseline Characteristics by eGFR Category.
| eGFR>90 mL/min/1.73 m2 | eGFR 60–90 mL/min/1.73 m2 | P Value | |
| Number | 998 | 854 | |
| Age | 56 (50–62) | 63 (56–68) | <0.001 |
| Gender | 0.027 | ||
| Men | 61.4% | 66.4% | |
| Women | 38.6% | 33.6% | |
| Race | <0.001 | ||
| White | 54.1% | 67.1% | |
| Black | 39.8% | 27.5% | |
| Other | 6.1% | 5.4% | |
| Hypertension | 73% | 81% | <0.001 |
| Systolic BP (mmHg) | 130 (121–140) | 131 (121–143) | 0.12 |
| Diastolic BP (mmHg) | 77 (72–83) | 75 (71–81) | 0.001 |
| Waist Circumference (in) | 106 (97–117) | 107 (97–116) | 0.95 |
| BMI (kg/m2) | 32 (28–37) | 32 (28–36) | 0.20 |
| Glucose (mg/dL) | 121 (96–155) | 112 (94–138) | <0.001 |
| Hemoglobin A1c (%) | 6.8 (6.2–8) | 6.7 (6.1–7.4) | <0.001 |
| HOMA-IR | 4.68 (3.04–7.87) | 4.29 (2.77–6.68) | 0.10 |
| Serum Creatinine (mg/dL) | 0.8 (0.7–0.89) | 1.0 (0.9–1.1) | <0.001 |
| BUN (mg/dL) | 13 (11–16) | 17 (14–19) | <0.001 |
| eGFR (CKD-EPI) | 101.2 (95.48–109.45) | 78.82 (72.09–84.69) | <0.001 |
| Urinary ACR (mg/g) | 4.9 (3–18.2) | 5.3 (3–17.5) | 0.04 |
| Anti-Hypertensive Medications | |||
| ACE Inhibitor or ARB | 56.1% | 65.1% | <0.001 |
| Diuretic | 24.6% | 33.7% | <0.001 |
| CCB | 14.6% | 20.5% | 0.001 |
| Beta Blocker | 12.0% | 16.1% | 0.01 |
| Lipid-Lowering Medications | |||
| Statin | 51.4% | 59.4% | <0.001 |
| Fibrate | 4.3% | 7.5% | 0.003 |
| Niacin | 5.6% | 5.7% | 0.77 |
Categorical variables are shown as proportions; continuous variables as median values (IQR). Abbreviations: BP blood pressure, BMI body mass index, HOMA-IR homeostatic model assessment of insulin resistance, BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, ACR albumin to creatinine ratio, CCB calcium channel blocker.